immunotherapy: toxicity, pseudo-progression, and varied responses
Published 9 years ago • 950 plays • Length 6:03Download video MP4
Download video MP3
Similar videos
-
7:38
pseudoprogression on immunotherapy in hnscc
-
4:57
pseudoprogression on immunotherapy in squamous nsclc
-
6:42
pseudoprogression with checkpoint inhibitors in non-small cell lung cancer
-
10:35
measuring response to immunotherapy in melanoma
-
4:29
abscopal effect and pseudoprogression in melanoma
-
4:06
immunotherapy toxicity profile
-
0:50
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
10:28
responses to traditional chemotherapy vs immunotherapy
-
4:26
patient selection for checkpoint inhibitor therapy and assessing response
-
40:37
webinar on "tumor treatment and pseudo progression - where are we"
-
1:14
dr. kim addresses concerns about hyperprogression in nsclc
-
4:33
overall toxicities with immunotherapy in melanoma
-
8:56
managing toxicity of immunotherapy in melanoma
-
4:21
immunotherapy-related pulmonary toxicities in melanoma
-
5:22
treatment for nsclc after progression on immunotherapy
-
1:51
jeffrey weber explains organ-specific side effects of checkpoint inhibitors
-
4:48
immune-related response criteria in nsclc
-
3:02
slcvl raez #11 time to response on immune checkpoint inhibitors and the concept of pseudoprogression
-
8:22
what to do after progression on immunotherapy and for non-driver nsclc